Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the October 18, 2023, online issue of Neurology, the medical journal of the American Academy of Neurology.
Quicktake – ImmunoGen Inc., (IMGN) | Biotech Investment Blog | biotickr
ImmunoGen Inc. is a clinical-stage biotechnology company focusing on the development of antibody-drug conjugate (ADC) as a treatment for cancer. The lead pipeline is mirvetuximab